Stocks and InvestingStocks and Investing
Wed, October 4, 2017
Tue, October 3, 2017
Mon, October 2, 2017
Fri, September 29, 2017
Thu, September 28, 2017
Wed, September 27, 2017
Tue, September 26, 2017
Mon, September 25, 2017
Fri, September 22, 2017
Thu, September 21, 2017

David Lebovitz Maintained (ALNY) at Hold with Increased Target to $101 on, Sep 21st, 2017


Published on 2024-10-25 22:56:26 - WOPRAI, David Lebovitz
  Print publication without navigation


David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Increased Target from $50 to $101 on, Sep 21st, 2017.

David has made no other calls on ALNY in the last 4 months.



There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 0 agree with David's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with David


  • Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $99 on, Friday, September 8th, 2017